We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
-25.9%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
-$298M
Cap. Flow
+$76.8M
Cap. Flow %
9.71%
Top 10 Hldgs %
95.26%
Holding
17
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
VIGL
Vigil Neuroscience
VIGL
+$77M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$254K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$8.25B
$291M 36.79%
6,875,698
– –
DYN icon
2
Dyne Therapeutics
DYN
$4.71B
$86.1M 10.89%
8,934,902
– –
DAWN
3
DELISTED
Day One Biopharmaceuticals
DAWN
$81.4M 10.29%
8,201,638
– –
GBIO
4
DELISTED
Generation Bio
GBIO
$60.8M 7.68%
827,888
– –
JBIO
5
Jade Biosciences
JBIO
$1.17B
$56.9M 7.19%
88,682
– –
REPL icon
6
Replimune Group
REPL
$1B
$54.5M 6.89%
3,209,627
– –
VIGL
7
DELISTED
Vigil Neuroscience
VIGL
$41M 5.19%
+5,836,874
New +$77M
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$31.7M 4%
2,232,251
– –
IMA
9
ImageneBio Inc
IMA
$64.2M
$30.6M 3.87%
418,182
– –
XLO icon
10
Xilio Therapeutics
XLO
$59.5M
$19.5M 2.47%
197,096
– –
DNTH icon
11
Dianthus Therapeutics
DNTH
$5.8B
$10.1M 1.27%
217,284
– –
SPRO icon
12
Spero Therapeutics
SPRO
$66.6M
$8.97M 1.13%
1,031,160
– –
IRON icon
13
Disc Medicine
IRON
$2.93B
$7.3M 0.92%
175,146
– –
TECX
14
Tectonic Therapeutic
TECX
$527M
$5.97M 0.75%
376,739
– –
FSTX
15
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.13M 0.27%
599,524
– –
VRDN icon
16
Viridian Therapeutics
VRDN
$2.13B
$1.67M 0.21%
90,072
– –
COGT icon
17
Cogent Biosciences
COGT
$6.64B
$1.4M 0.18%
186,487
-36,489
-16% -$254K

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Atlas Venture Life Science Advisors held 17 positions worth $791M, down 27% from $1.09B the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Atlas Venture Life Science Advisors deployed $76.8M of net new capital in Q1 2022, opening 1 new position. Its largest new stake was Vigil Neuroscience: 5,836,874 shares worth $41M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cogent Biosciences, an estimated $254K trimmed.

  • Atlas Venture Life Science Advisors's largest Q1 2022 buy was Vigil Neuroscience: 5,836,874 shares worth $41M.
  • Atlas Venture Life Science Advisors's biggest Q1 2022 reduction was Cogent Biosciences, cutting an estimated $254K.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 95% of its $791M portfolio in Q1 2022.
  • Atlas Venture Life Science Advisors opened 1 new position and closed 0 in Q1 2022.
  • Atlas Venture Life Science Advisors's portfolio value fell 27% quarter-over-quarter to $791M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2022, filed 16 May 2022.